Byoung Chul Cho, MD, PhD

Byoung Chul Cho, MD, PhD, is a professor of internal medicine in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine.

Articles by Byoung Chul Cho, MD, PhD

Enhanced Prophylactic Regimen Reduces Skin AEs With Amivantamab-Lazertinib: Byoung Chul Cho, MD, PhD

ByByoung Chul Cho, MD, PhD,Rose McNulty

September 9th 2025

Byoung Chul Cho, MD, PhD, of the Yonsei University College of Medicine, discussed outcomes in the COCOON trial of an enhanced dermatologic regimen with amivantamab-lazertinib treatment.

Byoung Chul Cho, MD, PhD

Articles by Byoung Chul Cho, MD, PhD

Enhanced Prophylactic Regimen Reduces Skin AEs With Amivantamab-Lazertinib: Byoung Chul Cho, MD, PhD

Latest Updated Articles

Trending on AJMC

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Clinicians Confront Fragmented Care and the Silent Burden of Undertreated Atopic Dermatitis

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Byoung Chul Cho, MD, PhD

Articles by Byoung Chul Cho, MD, PhD

Enhanced Prophylactic Regimen Reduces Skin AEs With Amivantamab-Lazertinib: Byoung Chul Cho, MD, PhD

Latest Updated Articles

Trending on AJMC

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Clinicians Confront Fragmented Care and the Silent Burden of Undertreated Atopic Dermatitis

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

Zanubrutinib Tops Rivals in Real-World CLL Survival Study